Evidence map›Paper›PMID 35160177›Full record

ReviewJournal of clinical medicine2022

Myeloid-Derived Suppressor Cells (MDSC) in the Umbilical Cord Blood: Biological Significance and Possible Therapeutic Applications.

Nikoleta Bizymi, Anthie Georgopoulou, Natalia Mastrogamvraki, Angelos Matheakakis, Ioanna Gontika, Irene Fragiadaki, Irene Mavroudi, Helen A Papadaki

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nikoleta BizymiDepartment of Haematology, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.ORCID 0000-0001-5199-1519
Anthie GeorgopoulouPublic Cord Blood Bank of Crete, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.
Natalia MastrogamvrakiPublic Cord Blood Bank of Crete, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.
Angelos MatheakakisDepartment of Haematology, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.
Ioanna GontikaPublic Cord Blood Bank of Crete, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.ORCID 0000-0003-0554-6697
Irene FragiadakiPublic Cord Blood Bank of Crete, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.
Irene MavroudiDepartment of Haematology, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.ORCID 0000-0002-7395-7896
Helen A PapadakiDepartment of Haematology, University Hospital of Heraklion, 71500 Heraklion, Crete, Greece.ORCID 0000-0002-5146-9699

Funding

Public Investment Fund 135857/18-06-2018University of Crete Maria Michail Manassaki Scholarship to Nikoleta Bizymi
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that suppress immune responses in cancer, infection, and trauma. They mainly act by inhibiting T-cells, natural-killer cells, and dendritic cells, and also by inducing T-regulatory cells, and modulating macrophages. Although they are mostly associated with adverse prognosis of the underlying disease entity, they may display positive effects in specific situations, such as in allogeneic hematopoietic stem cell transplantation (HSCT), where they suppress graft-versus-host disease (GVHD). They also contribute to the feto-maternal tolerance, and in the fetus growth process, whereas several pregnancy complications have been associated with their defects. Human umbilical cord blood (UCB) is a source rich in MDSCs and their myeloid progenitor cells. Recently, a number of studies have investigated the generation, isolation, and expansion of UCB-MDSCs for potential clinical application associated with their immunosuppressive properties, such as GVHD, and autoimmune and inflammatory diseases. Given that a significant proportion of UCB units in cord blood banks are not suitable for clinical use in HSCT, they might be used as a significant source of MDSCs for research and clinical purposes. The current review summarizes the roles of MDSCs in the UCB, as well as their promising applications.

Indexed as

autoimmunityfeto-maternal immune-tolerancegraft-versus-host disease (GVHD)immunologyimmunotherapyinfectioninflammationmyeloid-derived suppressor cell (MDSC)umbilical cord blood (UCB)

Identifiers

PMID35160177
PMCPMC8836851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.